Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight The SLE clinical trial analysis report delivers ...

Systemic lupus erythematosus (SLE) phenotype may be more informative than generic cardiovascular risk stratification.

Anifrolumab treatment is linked to improved disease activity and reduced steroid use and has an acceptable safety profile in routine care of patients with systemic lupus erythematosus.

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder in which the body’s immune system mistakenly attacks its own healthy tissues. This condition can affect multiple organs, including ...

A pivotal trial of obinutuzumab has demonstrated the strongest evidence yet of the efficacy of B-cell depletion in systemic ...

Investigators studied GLP-1 receptor agonist use and renal and inflammatory outcomes among patients with systemic lupus erythematosus and type 2 diabetes mellitus.

Fast Track Designation recognizes both the urgent need for new therapies in pMN and the compelling early clinical activity generated to date with budoprutug,” said Edgar Charles, M.D., Chief Medical ...

The Systemic Lupus Erythematosus SLE Drugs Market demonstrates a consistent upward trajectory, supported by innovation and increasing patient demand. From a base of USD 203.6 million in 2024, the ...

A new study found early hydroxychloroquine (HCQ) use offers no protection against preeclampsia or preterm birth in women with systemic lupus erythematosus (SLE).

Objectives Fatigue is one of the most common and debilitating symptoms experienced by patients with systemic lupus erythematosus (SLE). Previous studies revealed the association of fatigue with ...